A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone
dc.contributor.author | Newcomer J.W. | |
dc.contributor.author | Ratner R.E. | |
dc.contributor.author | Eriksson J.W. | |
dc.contributor.author | Emsley R. | |
dc.contributor.author | Meulien D. | |
dc.contributor.author | Miller F. | |
dc.contributor.author | Leonova-Edlund J. | |
dc.contributor.author | Leong R.W. | |
dc.contributor.author | Brecher M. | |
dc.date.accessioned | 2011-05-15T16:01:56Z | |
dc.date.available | 2011-05-15T16:01:56Z | |
dc.date.issued | 2009 | |
dc.description.abstract | Objective: This randomized, 24-week, flexible-dose study compared changes in glucose metabolism in patients with DSM-IV schizophrenia receiving initial exposure to olanzapine, quetiapine, or risperidone. Method: The hypothesized primary endpoint was change (baseline to week 24) in area under the curve (AUC) 0- to 2-hour plasma glucose values during an oral glucose tolerance test (OGTT); primary analysis: olanzapine versus quetiapine. Secondary endpoints included mean change in AUC 0- to 2-hour plasma insulin values, insulin sensitivity index, and fasting lipids. The first patient enrolled on April 29, 2004, and the last patient completed the study on October 24, 2005. Results: Mean weight change (kg) over 24 weeks was +3.7 (quetiapine), +4.6 (olanzapine), and +3.6 (risperidone). Based on data from 395 patients (quetiapine, N = 115 [mean dose = 607.0 mg/day], olanzapine, N = 146 [mean dose = 15.2 mg/day], and risperidone, N = 134 [mean dose = 5.2 mg/day]), mean change in AUC 0- to 2-hour glucose value (mg/dL x h) at week 24 was significantly lower for quetiapine versus olanzapine (t = 1.98, df = 377, p = .048). Increases in AUC 0- to 2-hour glucose values were statistically significant with olanzapine (+21.9 mg/dL x h, 95% CI = 11.5 to 32.4 mg/dL x h) and risperidone (+18.8 mg/dL x h, 95% CI = 8.1 to 29.4 mg/dL x h), but not quetiapine (+9.1 mg/dL x h, 95% CI = -2.3 to 20.5 mg/dL x h). AUC 0- to 2-hour insulin values increased statistically significantly with olanzapine (+24.5%, 95% CI = 11.5% to 39.0%), but not with quetiapine or risperidone. Reductions in insulin sensitivity index were statistically significant with olanzapine (-19.1%, 95% CI = -27.9% to -9.3%) and risperidone (-15.8%, 95% CI = -25.1% to -5.4%), but not quetiapine. Total cholesterol and low-density lipoprotein levels increased statistically significantly with olanzapine (+21.1 mg/dL, 95% CI = 13.0 to 29.2 mg/dL, and +20.5 mg/dL, 95% CI = 13.8 to 27.1 mg/dL, respectively) and quetiapine (+13.1 mg/dL, 95% CI = 4.3 to 21.9 mg/dL, and +13.3 mg/dL, 95% CI = 6.1 to 20.5 mg/dL, respectively), but not risperidone. Statistically significant increases in triglycerides (+30.9 mg/dL, 95% CI = 10.9 to 51.0 mg/dL), total cholesterol/high-density lipoprotein (HDL) ratio (0.5, 95% CI = 0.2 to 0.8), and triglyceride/HDL ratio (0.3, 95% CI = 0.0 to 0.6) were observed with olanzapine only. Conclusion: The results indicate a significant difference in the change in glucose tolerance during 6 months' treatment with olanzapine versus quetiapine, with significant reductions on olanzapine and risperidone, but not quetiapine; these differential changes were largely explained by changes in insulin sensitivity. Trial Registration: clinicaltrials.gov Identifier: NCT00214578. © Copyright 2009 Physicians Postgraduate Press, Inc. | |
dc.description.version | Article | |
dc.identifier.citation | Journal of Clinical Psychiatry | |
dc.identifier.citation | 70 | |
dc.identifier.citation | 4 | |
dc.identifier.issn | 1606689 | |
dc.identifier.other | 10.4088/JCP.08m04132 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/12224 | |
dc.subject | lipid | |
dc.subject | olanzapine | |
dc.subject | quetiapine | |
dc.subject | risperidone | |
dc.subject | adult | |
dc.subject | akathisia | |
dc.subject | article | |
dc.subject | cholesterol blood level | |
dc.subject | clinical trial | |
dc.subject | controlled clinical trial | |
dc.subject | controlled study | |
dc.subject | delusion | |
dc.subject | dizziness | |
dc.subject | drug withdrawal | |
dc.subject | dyspnea | |
dc.subject | dystonia | |
dc.subject | extrapyramidal syndrome | |
dc.subject | female | |
dc.subject | glucose blood level | |
dc.subject | glucose metabolism | |
dc.subject | glucose tolerance | |
dc.subject | hallucination | |
dc.subject | headache | |
dc.subject | human | |
dc.subject | hypertension | |
dc.subject | insomnia | |
dc.subject | insulin blood level | |
dc.subject | insulin sensitivity | |
dc.subject | lipid blood level | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | multicenter study | |
dc.subject | neutrophil count | |
dc.subject | open study | |
dc.subject | oral glucose tolerance test | |
dc.subject | panic | |
dc.subject | priority journal | |
dc.subject | psychosis | |
dc.subject | randomized controlled trial | |
dc.subject | restlessness | |
dc.subject | schizophrenia | |
dc.subject | sedation | |
dc.subject | side effect | |
dc.subject | somnolence | |
dc.subject | thorax pain | |
dc.subject | treatment duration | |
dc.subject | triacylglycerol blood level | |
dc.subject | upper abdominal pain | |
dc.subject | weight gain | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Antipsychotic Agents | |
dc.subject | Benzodiazepines | |
dc.subject | Cholesterol, HDL | |
dc.subject | Cholesterol, LDL | |
dc.subject | Dibenzothiazepines | |
dc.subject | Female | |
dc.subject | Glucose | |
dc.subject | Humans | |
dc.subject | Insulin | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Risperidone | |
dc.subject | Schizophrenia | |
dc.subject | Triglycerides | |
dc.subject | Young Adult | |
dc.title | A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone | |
dc.type | Article |